Dr. Saadia Chohan, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 6
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 705
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license OK18115
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- O U Medical Center Oklahoma City, OK
- Integris Baptist Medical Center, Inc Oklahoma City, OK
- Ssm Health St Anthony Hospital - Oklahoma City Oklahoma City, OK
- Ssm Health St Anthony Hospital - Shawnee Shawnee, OK
- Onecore Health Oklahoma City, OK
Medical groups
- Saints Medical Group, LLC (435 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 705
- Services billed
- 11,031
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9,600 | 66 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,243 | 387 |
| Established patient office or other outpatient visit, 20-29 minutes | 618 | 411 |
| New patient office or other outpatient visit, 45-59 minutes | 117 | 117 |
| Ct scan of abdomen and pelvis with contrast | 60 | 44 |
| Ct scan of chest with contrast | 49 | 38 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 46 | 43 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 38 | 36 |
| Ct scan of chest without contrast | 20 | 14 |
| Ct scan of abdomen and pelvis without contrast | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Oklahoma City, OK | 356 |
| Hydroxyurea Other prescribers in Oklahoma City, OK | 209 |
| Ondansetron Hcl Other prescribers in Oklahoma City, OK | 110 |
| Letrozole Other prescribers in Oklahoma City, OK | 89 |
| Jakafi (ruxolitinib phosphate) | 84 |
| Dexamethasone Other prescribers in Oklahoma City, OK | 70 |
| Prednisone Other prescribers in Oklahoma City, OK | 66 |
| Imatinib Mesylate | 61 |
| Prochlorperazine Maleate Other prescribers in Oklahoma City, OK | 60 |
| Potassium Chloride Other prescribers in Oklahoma City, OK | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 42 companies reported 124 payments worth $3,459 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,284 |
|---|---|
| Pfizer Inc. | $251 |
| AstraZeneca Pharmaceuticals LP | $235 |
| Array Biopharma Inc | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | $122 |
| Daiichi Sankyo Inc. | $103 |
| AbbVie Inc. | $99.11 |
| GlaxoSmithKline, LLC. | $72.66 |
| Food and Beverage | $2,092 |
|---|---|
| Long term medical supply or device loan | $1,180 |
| Education | $186 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Nov 17, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Sep 5, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Sep 5, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Sep 5, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Aug 9, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Jul 3, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Jul 3, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Jul 3, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $10.54 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Jun 4, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. May 12, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Pfizer Inc. Feb 25, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $11.88 |
| Pfizer Inc. Feb 25, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $7.98 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.